Memuatkan

Slzii.com Cari

Cari (Berita)
Novo Nordisk A/S: Cagrisema Demonstrated 23% Weight Loss In An Open-Label Head-To-Head REDEFINE 4 Trial In People With Obesity, The Primary Endpoint Was Not Achieved
(MENAFN - GlobeNewsWire - Nasdaq) CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss ...
2026-02-23 04:46:12

awak buat apa?
0.042799949645996


Berita
Berita

Berita dan Tajuk Berita Terkini
(MENAFN - GlobeNewsWire - Nasdaq) CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the prima...
Berita